CalciMedica Reports Strong Phase 2b Auxora Data in Acute Pancreatitis; Awaits FDA Feedback & Q1 Net Income

summarizeSummary

CalciMedica reported strong Phase 2b clinical trial results for its lead candidate Auxora in acute pancreatitis and achieved a Q1 net income driven by non-operating gains, with a cash runway into Q4 2026.

check_boxKey Events

• Strong Phase 2b Auxora Results

  Detailed positive results from the Phase 2b CARPO trial for Auxora in acute pancreatitis (AP) were published, demonstrating clinically meaningful and statistically significant improvements, including a 100% reduction in new-onset severe respiratory failure.

• Key FDA Milestones Ahead

  The company expects FDA feedback in Q2 2026 on the pivotal program design for Auxora in AP and potential future development in acute kidney injury (AKI), following a positive safety review after pausing the AKI trial.

• Q1 Net Income Driven by Non-Operating Gains

  CalciMedica reported a net income of $5.0 million for Q1 2026, primarily due to a $10.8 million fair value adjustment of financial instruments, rather than operational profitability.

• Limited Cash Runway

  Cash and cash equivalents stood at $8.2 million as of March 31, 2026, with an expected cash runway into the fourth quarter of 2026, highlighting continued financing needs.

auto_awesomeAnalysis

CalciMedica announced positive Phase 2b results for Auxora in acute pancreatitis, showing statistically significant reductions in severe respiratory failure and improved clinical outcomes. This strong data, coupled with expected FDA feedback in Q2 2026, is critical for the company's lead program. While Q1 showed a net income, it was primarily due to non-operating fair value adjustments, and the company's cash runway extends only into Q4 2026, indicating an ongoing need for financing.